131 related articles for article (PubMed ID: 15767790)
1. Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma.
Massacesi C; Burattini L; Marcucci F; Bonsignori M
J Interferon Cytokine Res; 2005 Mar; 25(3):165-8. PubMed ID: 15767790
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Fuxius S; Mross K; Mansouri K; Unger C
Anticancer Drugs; 2002 Oct; 13(9):899-905. PubMed ID: 12394252
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Ryan CW; Vogelzang NJ; Stadler WM
Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
Perez-Zincer F; Olencki T; Budd GT; Peereboom D; Elson P; Bukowski RM
Invest New Drugs; 2002 Aug; 20(3):305-10. PubMed ID: 12211213
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
[TBL] [Abstract][Full Text] [Related]
8. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Falcone A; Cianci C; Pfanner E; Ricci S; Lencioni M; Brunetti I; Giulianotti PC; Vannucci L; Mosca F; Conte PF
Ann Oncol; 1996 Aug; 7(6):601-5. PubMed ID: 8879374
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Small EJ
Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
[TBL] [Abstract][Full Text] [Related]
13. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
Cancer; 2002 Oct; 95(8):1629-36. PubMed ID: 12365009
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
[TBL] [Abstract][Full Text] [Related]
15. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Rebmann U; Soder M; Gertenbach U; Siebels M; Roigas J; Raschke R; Salm S; Schwindl B; Müller SC; Hauser S; Leiber C; Huland E; Heinzer H; Siemer S; Metzner B; Heynemann H; Fornara P; Reitz M
Br J Cancer; 2006 Aug; 95(4):463-9. PubMed ID: 16909131
[TBL] [Abstract][Full Text] [Related]
17. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
18. A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population.
Clark JI; Kuzel TM; Lestingi TM; Fisher SG; Sorokin P; Martone B; Viola M; Sosman JA
Ann Oncol; 2002 Apr; 13(4):606-13. PubMed ID: 12056712
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
[TBL] [Abstract][Full Text] [Related]
20. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
